Drug shows promise in keeping aggressive leukemia at bay after transplant
NCT ID NCT06734585
Summary
This study looked at whether the drug gilteritinib helps keep acute myeloid leukemia (AML) from returning after a stem cell transplant in patients with a specific genetic change (FLT3). Researchers compared two groups: one from previous trials who received gilteritinib after transplant, and another group from medical records who received standard care. The goal was to see which approach led to longer periods without the cancer coming back. No new treatments were given; this was an analysis of existing information.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AU61001
Melbourne, Australia
-
AU61002
Melbourne, Australia
-
BR55001
São Paulo, Brazil
-
BR55002
Porto Alegre, Brazil
-
BR55003
São Paulo, Brazil
-
BR55004
Fortaleza, Brazil
-
CN86001
Tianjin, China
-
CN86003
Shanghai, China
-
CN86004
Suzhou, China
-
HK852001
Hong Kong, Hong Kong
-
KR82001
Seoul, South Korea
-
KR82002
Seoul, South Korea
-
KR82003
Seoul, South Korea
-
KR82004
Busan, South Korea
-
KR82005
Gwangju, South Korea
-
TW88601
Taipei, Taiwan
-
TW88602
Tainan, Taiwan
-
TW88603
Taichung, Taiwan
Conditions
Explore the condition pages connected to this study.